Can I read Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway on EtoBox?

Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway by Hao Wang; Yu-chen Liu; Cheng-ying Zhu; Fei Yan; Meng-zhen Wang; Xiao-su Chen; Xiao-kai Wang; Bao-xu Pang; Yong-hui Li; Dai-hong Liu; Chun-ji Gao; Shu-jun Liu; Li-ping Dou is a Biochemistry, Genetics and Molecular Biology article available to read on EtoBox.

What is Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway about?

## Abstract ## Background Induction therapy for acute myeloid leukemia (AML) is an anthracycline-based chemotherapy regimen. However, many patients experience a relapse or exhibit refractory disease (R/R). There is an urgent need for more effective regimens to reverse anthracycline resistance in these patients. ## Methods In this paper, Twenty-seven R/R AML patients with anthracycline resistance consecutively received chidamide in combination with anthracycline-based regimen as salvage therapy at the Chinese PLA General Hospital. ## Results Of the 27 patients who had received one course of salvage therapy, 13 achieved a complete response and 1 achieved a partial response. We found that the HDAC3-AKT-P21-CDK2 signaling pathway was significantly upregulated in anthracycline-resistant AML cells compared to non-resistant cells. AML patients with higher levels of HDAC3 had lower event-free survival (EFS) and overall survival (OS) rates. Moreover, anthracycline-resistant AML cells are susceptible to chidamide, a histone deacetylase inhibitor which can inhibit cell proliferation, increase cell apoptosis and induce cell-cycle arrest in a time- and dose-dependent manner. Chidamide increases

Who reads Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway?

Author

Hao Wang; Yu-chen Liu; Cheng-ying Zhu; Fei Yan; Meng-zhen Wang; Xiao-su Chen; Xiao-kai Wang; Bao-xu Pang; Yong-hui Li; Dai-hong Liu; Chun-ji Gao; Shu-jun Liu; Li-ping Dou

Publisher

BioMed Central; Springer (Biomed Central Ltd.); London: BioMed Central, 2008-; Springer Science and Business Media LLC; Society for Mining, Metallurgy and Exploration Inc. (ISSN 1756-9966)

Published

2020

Language

EN

Field

Biochemistry, Genetics and Molecular Biology (Life Sciences)